Skip to main content

View full-text article in PMC

. 2018 Oct 30;9(85):35528–35540. doi: 10.18632/oncotarget.26217

Table 1. Prognostic determinants in LUAD versus LUSC.

LUSC prognostic determinants
°LUSC diagnosis^a
▪Protective factors: DSG3, SERPINB13, MRP5, FOXE1, GRHL3, DLX5 ▪Tumor progression determinants: SFN
°LUAD diagnosis ^b
▪Protective factors: FOLR1, PLEKHA6 ▪Tumor progression determinants: SFTA3
°Not associated to diagnosis ^c
▪Protective factors: SKP2, TGFBR2 ▪Tumor progression determinants: MPP5, E2F

LUAD prognostic determinants
°LUSC diagnosis^a
▪Protective factors: ATP1B3, HPCAL3, SFTA2, COL4A6, MRP5, SLUG, PARD6G, SOX2, CLCA2, RPTPB, JAG1, STF1 ▪Tumor progression determinants: KRT5A, KRT6A, KRT14, KRT17, PERP, SERPINB5, SERPINB13, COL7A1, DSG3, TRIM29, FGFBP1, GLUT1, SFN, TMPRS11D, FOXE1, GRHL3, PTHLH, S100A1, DLX5, ST6GALNAC2
°LUAD diagnosis ^b
▪Protective factors: TMEM125, TTF1, TASK2, TMC5, ACSL5, FOLR1, RORC, QSOX1, SFTA3, CEACAM6, ATP11A, PLEKHA6 ▪Tumor progression determinants: KRT7, TESC, CLDN3
°Not associated to diagnosis ^c
▪Protective factors: GSK3B, ATR, SKP2, SMC3, CCND3, PRIM2, IGF1R, TGFBR2, CTNND1, CASK, MPP5, CTGF, PDGFA ▪Tumor progression determinants: PRPF19, MCM4, MCM5, RFC2, PLK1, CDK2, PDGFB, E2F

^aUtilized for LUSC diagnosis.

^bUtilized for LUAD diagnosis.

^cCancer drivers that are not utilized for differential diagnosis of NSCLC subtypes.